![Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial - The Lancet Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/4b7e768e-047f-4bfb-834a-78ab10e744e8/gr2_lrg.jpg)
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial - The Lancet
![Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial - The Lancet Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/49f40097-6e0d-4932-85b8-0be2c505a647/gr1.gif)
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial - The Lancet
![Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial - The Lancet Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/2d7ab7e8-6065-4744-b7d3-4b10e65cd978/gr1_lrg.jpg)
Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial - The Lancet
![Cancer and Genome: Bioinformatics, Biostatistics and Epidemiology of Complex Systems (U900) | Institut Curie Cancer and Genome: Bioinformatics, Biostatistics and Epidemiology of Complex Systems (U900) | Institut Curie](https://institut-curie.org/sites/default/files/styles/header_sciences/public/medias/images/2021-07/couv_30.jpg?h=aabbdb8b&itok=3WCFR1QP)
Cancer and Genome: Bioinformatics, Biostatistics and Epidemiology of Complex Systems (U900) | Institut Curie
![Cancers | Free Full-Text | Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives Cancers | Free Full-Text | Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives](https://pub.mdpi-res.com/cancers/cancers-13-04840/article_deploy/html/images/cancers-13-04840-ag-550.jpg?1632896682)